This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
This week, we will discuss a pilot trial of using mannitol to treat intradialytic hypotension. A daily occurence in our practice, hence providing some much needed data.
We will be discussing a systematic review on treatment options for uremic pruritis. Such a simple symptom can be so bothersome, and is so common. Join us as we discuss the options on Sep 27
Could running marathons be hard on your kidneys, or at least biomarkers that track kidney injury> this paper in AJKD seems to suggest so. Join us to discuss this intriguing data and whether it should impact on runners, on May 23 and 24th.